BNF April 2023 Update

This update contains 2 significant changes, 1 dose change, 5 new monographs, and 2 deleted monographs.

Significant Changes:

• Metolazone (Xaqua®): exercise caution when switching patients between metolazone preparations [MHRA/CHM advice].
• Testosterone (Testogel®): risk of harm to children following accidental exposure [MHRA/CHM advice].

Dose Change:

• Cefotaxime [update to dosing for emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital].

New Monographs:

• Lamzede® [velmanase alfa].
• Livtencity® [maribavir].
• Nexviadyme® [avalglucosidase alfa].
• Perindopril erbumine with amlodipine.
• Rezurock® [belumosudil].

Deleted Monographs:

• Bleomycin.
• Vinflunine.